CalciMedica Inc. (NASDAQ:CALC) Given Average Recommendation of “Hold” by Analysts

CalciMedica Inc. (NASDAQ:CALC) has earned an average recommendation of “Hold” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.00.

CALC has been the topic of a number of research analyst reports. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Weiss Ratings cut shares of CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a research report on Saturday, August 22nd. Finally, Guggenheim started coverage on shares of CalciMedica in a research note on Thursday, August 20th. They issued a “buy” rating for the company.

Insider Activity at CalciMedica

In other news, Director Fred A. Middleton purchased 248,972 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the transaction, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This trade represents a 30.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 28.25% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CalciMedica

A number of institutional investors have recently added to or reduced their stakes in CALC. Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares in the last quarter. 180 Wealth Advisors LLC increased its stake in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after acquiring an additional 94,650 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after acquiring an additional 39,775 shares in the last quarter. Jane Street Group LLC purchased a new position in CalciMedica during the 4th quarter valued at about $127,000. Finally, Envestnet Asset Management Inc. lifted its position in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the period.

CalciMedica Price Performance

Shares of CALC stock opened at $0.59 on Thursday. The firm has a market cap of $20.06 million, a P/E ratio of -0.43 and a beta of 0.91. CalciMedica has a fifty-two week low of $0.46 and a fifty-two week high of $7.20. The business’s 50 day moving average price is $0.76 and its 200-day moving average price is $0.70. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). On average, equities research analysts anticipate that CalciMedica will post -1.05 earnings per share for the current year.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.